Table 1.
Characteristics of the participating studies from lung, colorectal, breast, prostate and ovary cancer consortium
| Cancer | Study, No. | Case patients, No. | Control patients, No. | Genotyping platform | Reference panel | Covariates | Refs |
|---|---|---|---|---|---|---|---|
| Lung - overall | 9 | 14 900 | 29 485 | Illumina 317K/550K/610K | HapMap2 | Age, sex, PCs | (20) |
| Adenocarcinoma | 9 | 4813 | 28 489 | Illumina 317K/550K/610K | HapMap2 | Age, sex, PCs | |
| Squamous cell | 9 | 4110 | 28 643 | Illumina 317K/550K/610K | HapMap2 | Age, sex, PCs | |
| Colorectal - GECCO | 13 | 10 314 | 12 857 | Illumina 550K/610K/CytoSNP/Omni Affymetrix 100K/500K |
1000 Genome | Age, sex (when applicable), PCs | (26) |
| Colorectal - CORECT | 6 | 5100 | 4831 | Affymetrix Axiom | 1000 Genome | Age, sex, PCs | (28) |
| Ovary overall | 3 | 4369 | 9123 | Illumina 317K/370K/550K/610K/670K/2.5M | 1000 Genome | Site, PCs | (27) |
| Serous | 3 | 2556 | 9123 | Illumina 317K/370K/550K/610K/670K/2.5M | 1000 Genome | Site, PCs | |
| Endometroid | 3 | 715 | 9123 | Illumina 317K/370K/550K/610K/670K/2.5M | 1000 Genome | Site, PCs | |
| Breast overall | 11 | 15 748 | 18 084 | Illumina 317K//370K/550K/660K/1.2M | 1000 Genome | Age, PCs (vary by studies) | (23,30) |
| ER-negative | 8 | 4939 | 13 128 | Illumina 317K/370K/550K/660K/1.2M | 1000 Genome | Age, PCs (vary by studies) | (29) |
| Prostate overall | 6 | 14 160 | 12 724 | Illumina and Affymetrix arrays | 1000 Genome | Age, study | |
| Aggressive | 6 | 4939 | 12 724 | Illumina and Affymetrix arrays | 1000 Genome | Age, study, PCs | |
| Total* | 48 | 64 591 | 74 467 |
* Number of unique individuals after accounting for tumor subtypes and overlapping control patients. CORECT = ColoRectal Transdisciplinary Study; ER = estrogen receptor; GECCO = Genetics and Epidemiology of Colorectal Cancer Consortium; PCs = principal components representing residual European ancestry.